Used primarily in pharmaceutical research as a selective inhibitor of phosphodiesterase 10A (PDE10A), this compound is investigated for its potential in treating central nervous system disorders, particularly schizophrenia and other psychiatric conditions involving dopamine dysregulation. It modulates intracellular signaling in the striatal pathway, which plays a key role in cognitive and motor functions. Due to its ability to cross the blood-brain barrier and target specific brain regions, it serves as a valuable tool compound in neuropharmacology studies aimed at understanding basal ganglia function and developing novel antipsychotic agents.